Liposomal Bupivacaine Results in Cost Savings While Managing Post-Operative Pain in Fragility Intertrochanteric Hip Fractures

Nainisha Chintalapudi
nchintal@student.nymc.edu

Avinesh Agarwalla MD
Westchester Medical Center, avinesh.agarwalla@icloud.com

Joana Lu PA
Pomona Valley Hospital Medical Center, joana.lu@pvhmc.org

Hrayr G. Basmajian MD
Pomona Valley Hospital Medical Center, basmajianmd@gmail.com

Joseph N. Liu MD
Loma Linda Medical Center, jnliu@llu.edu

Follow this and additional works at: https://touroscholar.touro.edu/shspstudentresearchday

Part of the Clinical Epidemiology Commons, Community Health and Preventive Medicine Commons, Environmental Public Health Commons, Epidemiology Commons, Health Services Administration Commons, Health Services Research Commons, Other Public Health Commons, Physical Therapy Commons, and the Public Health Education and Promotion Commons

Chintalapudi, Nainisha; Agarwalla, Avinesh MD; Lu, Joana PA; Basmajian, Hrayr G. MD; Liu, Joseph N. MD; and Amin, Nirav H. MD, "Liposomal Bupivacaine Results in Cost Savings While Managing Post-Operative Pain in Fragility Intertrochanteric Hip Fractures" (2020). Annual SHSP Student Research and Scholarship Day. 2.
https://touroscholar.touro.edu/shspstudentresearchday/2020/policy/2

This Event is brought to you for free and open access by the Events at Touro Scholar. It has been accepted for inclusion in Annual SHSP Student Research and Scholarship Day by an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu.
Presenter Information
Nainisha Chintalapudi, Avinesh Agarwalla MD, Joana Lu PA, Hrayr G. Basmajian MD, Joseph N. Liu MD, and Nirav H. Amin MD

This event is available at Touro Scholar: https://touroscholar.touro.edu/shspstudentresearchday/2020/policy/2
TITLE: Liposomal Bupivacaine Results in Cost Savings While Managing Post-Operative Pain in Fragility Intertrochanteric Hip Fractures

BACKGROUND/OBJECTIVE: Intertrochanteric hip fractures are amongst the most common and most expensive diagnoses in the Medicare population. Opioids have long been the mainstay of treatment however, with their high risk of adverse events, especially in the elderly, there is an effort to find non-narcotic modalities of pain management. Liposomal bupivacaine (LB) is a novel preparation of a commonly used analgesic agent that when used intra-operatively decreases narcotic requirements, decreases hospital length of stay and increases likelihood of discharge to home. The objective of this study is to determine whether there is an economic benefit to utilizing intraoperative liposomal bupivacaine in patients with fragility intertrochanteric femur fractures in comparison to a group of patients who did not receive liposomal bupivacaine.

DESIGN/METHODS: Retrospective observational study at two academic medical centers. Fifty-six patients with intertrochanteric hip fractures treated with cephalomedullary nail implant who received standard hip fracture pain management protocol were compared to a cohort of forty-six patients with intertrochanteric hip fractures who received additional intraoperative injections of liposomal bupivacaine. All other standard of care was identical. Standard of care was set at P < 0.05.

RESULTS: Although the length of hospital stay was similar between the two groups (3.2 days vs 3.8 days, p = 0.08), patients receiving intraoperative liposomal bupivacaine had lower likelihood of discharge to skilled nursing facility (84.8% vs 96.4%, p = 0.002) and a longer operative time (73.4 min vs 67.2 min, p = 0.004). A cost benefit analysis indicated that for an investment of $320 in the administration of LB, there was a relative savings of $528.90 compared to the control group. The benefit:cost ratio was 1.65, indicating a $1.65 benefit for each $1 investing in liposomal bupivacaine.

CONCLUSIONS: Despite an increased initial cost, intra-operative use of liposomal bupivacaine was found to be a cost-effective intervention due to a higher likelihood of discharge to home during the postsurgical management of patients with intertrochanteric hip fractures.